MG
Marex Group Portfolio holdings
AUM
$23.6B
Turnover
47.63%
1-Year Est. Return
57.16%
This Fund
S&P 500
This Quarter
Est. Return
+4.95%
1 Year Est. Return
+57.16%
3 Year Est. Return
+254.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$15.8B
AUM Growth
-$67.5M
(-0.42%)
Cap. Flow
+$1.48B
Cap. Flow
% of AUM
9.36%
Top 10 Holdings %
Top 10 Hldgs %
30.69%
Holding
1,298
New
335
Increased
347
Reduced
276
Closed
290
Avg Time Held Equity + Options
0.7
years
Top 10 Avg Time Held Equity + Options
0.2
years
Top 20 Avg Time Held Equity + Options
0.5
years
Avg Time Held Equity only
0.7
years
Top 10 Avg Time Held Equity only
0.6
years
Top 20 Avg Time Held Equity only
0.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lumentum
LITE
|
+$471M |
| 2 |
Sandisk
SNDK
|
+$313M |
| 3 |
Goldman Sachs
GS
|
+$179M |
| 4 |
Invesco QQQ Trust
QQQ
|
+$144M |
| 5 |
Eli Lilly
LLY
|
+$113M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$304M |
| 2 |
UnitedHealth
UNH
|
+$174M |
| 3 |
NVIDIA
NVDA
|
+$137M |
| 4 |
Home Depot
HD
|
+$131M |
| 5 |
Netflix
NFLX
|
+$107M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 48.11% |
| 2 | Technology | 25% |
| 3 | Financials | 9.44% |
| 4 | Consumer Discretionary | 4.76% |
| 5 | Healthcare | 4.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
926
Biomea Fusion
BMEA
$60.5M
| $153K | ﹤0.01% |
100,000
| – | – |
2024 Q2
7 quarters
|
|
927
Orion Group Holdings
ORN
$348M
| $153K | ﹤0.01% |
+14,000
| New | +$168K |
2026 Q1
0 quarters
|
|
928
Banco Bradesco
BBD
$43.8B
| $150K | ﹤0.01% |
41,113
+7,699
| +23% | +$29.2K |
2024 Q2
7 quarters
|
|
929
Voyager Therapeutics
VYGR
$124M
| $148K | ﹤0.01% |
38,322
| – | – |
2024 Q4
5 quarters
|
|
930
LENZ Therapeutics
LENZ
$108M
| $146K | ﹤0.01% |
16,000
| – | – |
2025 Q4
1 quarter
|
|
931
Vital Farms
VITL
$383M
| $145K | ﹤0.01% |
10,250
-6,582
| -39% | -$156K |
2025 Q4
1 quarter
|
|
|
CEPT
932
DELISTED
Cantor Equity Partners II
CEPT
| $142K | ﹤0.01% |
+13,000
| New | +$149K |
2026 Q1
0 quarters
|
|
933
C3.ai
AI
$1.88B
| $140K | ﹤0.01% |
16,656
-2,977
| -15% | -$31.9K |
2025 Q4
1 quarter
|
|
934
Brookdale Senior Living
BKD
$2.41B
| $137K | ﹤0.01% |
+10,001
| New | +$140K |
2026 Q1
0 quarters
|
|
935
Schrodinger
SDGR
$1.87B
| $131K | ﹤0.01% |
+11,574
| New | +$160K |
2026 Q1
0 quarters
|
|
936
Nuveen California AMT-Free Quality Municipal Income Fund
NKX
$589M
| $125K | ﹤0.01% |
+10,510
| New | +$134K |
2026 Q1
0 quarters
|
|
937
ProShares UltraShort Bloomberg Crude Oil
SCO
$898M
| $125K | ﹤0.01% |
+3,750
| New | +$210K |
2026 Q1
0 quarters
|
|
938
Invesco Value Municipal Income Trust
IIM
$499M
| $124K | ﹤0.01% |
+10,200
| New | +$128K |
2026 Q1
0 quarters
|
|
939
5E Advanced Materials
FEAM
$127M
| $120K | ﹤0.01% |
85,812
-19,123
| -18% | -$45.5K |
2023 Q4
9 quarters
|
|
940
Cumberland Pharmaceuticals
CPIX
$112M
| $118K | ﹤0.01% |
+36,423
| New | +$140K |
2026 Q1
0 quarters
|
|
941
Cemex
CX
$13.7B
| $115K | ﹤0.01% |
10,020
-2,953
| -23% | -$35.2K |
2025 Q4
1 quarter
|
|
942
Lantronix
LTRX
$277M
| $105K | ﹤0.01% |
+20,000
| New | +$122K |
2026 Q1
0 quarters
|
|
943
Draganfly
DPRO
$153M
| $102K | ﹤0.01% |
+20,809
| New | +$154K |
2026 Q1
0 quarters
|
|
944
Recursion Pharmaceuticals
RXRX
$2.01B
| $101K | ﹤0.01% |
+32,788
| New | +$127K |
2026 Q1
0 quarters
|
|
945
Under Armour
UAA
$2.06B
| $99.3K | ﹤0.01% |
16,796
-89,337
| -84% | -$579K |
2025 Q3
2 quarters
|
|
946
POET Technologies
POET
$1.01B
| $98.9K | ﹤0.01% |
16,657
-12,343
| -43% | -$80K |
2025 Q2
3 quarters
|
|
947
Vir Biotechnology
VIR
$1.76B
| $98.6K | ﹤0.01% |
+11,000
| New | +$87.7K |
2026 Q1
0 quarters
|
|
948
BCP Investment Corp
BCIC
$84.3M
| $95.7K | ﹤0.01% |
12,722
-10,681
| -46% | -$116K |
2025 Q2
3 quarters
|
|
949
Pimco California Municipal Income Fund
PCQ
$146M
| $94.4K | ﹤0.01% |
+11,000
| New | +$97.9K |
2026 Q1
0 quarters
|
|
950
Mount Logan Capital Inc
MLCI
$35.1M
| $94.2K | ﹤0.01% |
26,325
+5,898
| +29% | +$37.3K |
2025 Q4
1 quarter
|
|
Similar funds
AF
NAM
ATO
DSA
A
Marex Group's Q1 2026 Portfolio in Review
As of Q1 2026, Marex Group held 1,298 positions worth $15.8B, down 0.42% from $15.9B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Marex Group deployed $1.48B of net new capital in Q1 2026, opening 335 new positions and adding to 347 existing holdings. Its largest new stake was Lumentum: 857,171 shares worth $602M.
By sector, the portfolio is most concentrated in Miscellaneous at 48% of assets, down from 51% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Meta Platforms (Facebook), an estimated $304M trimmed.
- Marex Group's largest Q1 2026 buy was Lumentum: 857,171 shares worth $602M.
- Marex Group added most to Goldman Sachs in Q1 2026, an estimated $179M increase.
- Marex Group's biggest Q1 2026 reduction was Meta Platforms (Facebook), cutting an estimated $304M.
- Marex Group fully exited Dycom Industries in Q1 2026, selling an estimated $13.3M.
- Marex Group's ten largest holdings make up 31% of its $15.8B portfolio in Q1 2026.
- Marex Group opened 335 new positions and closed 290 in Q1 2026.
- Marex Group's portfolio value fell 0.42% quarter-over-quarter to $15.8B.
Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.